Article Text

Download PDFPDF
Backwoods cigars release ‘California Range’ of products with concept flavour names
  1. Catherine Crawford Osborn,
  2. Stephanie Pike Moore,
  3. April Machta,
  4. Erika Trapl
  1. Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA
  1. Correspondence to Catherine Crawford Osborn, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106, USA; catherine.osborn{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Backwoods cigars, sold by Imperial Tobacco Group (ITG), have the fastest growing market share of cigar sales in USA.1 Since 2018, Backwoods’ advertising has previously characterised both their cigar products as ‘natural’ while focusing on their brand-specific flavours.2–4 Most Backwoods products sold are flavoured.5 Nearly all Backwoods products found in localities with flavour restrictions continue to have explicit characterising flavour names.6 7

In December 2022, the state of California implemented restrictions that prohibit the sale of flavoured tobacco products. In Spring 2023, Backwoods cigars’ website began featuring a new selection of seven products referred to as their California Range (figure 1). Whereas the Original and Craft Backwoods cigars—now collectively known as the National Range—primarily have explicit or characterising flavour names, California Range products have primarily concept flavour names.

Figure 1

Screen capture of Backwoods Original, Craft, and California Range Products.8

Review of Backwoods’ new California Range cigars against …

View Full Text


  • Twitter @erikatrapl

  • Contributors All authors took an active role in the manuscript. CCO, SPM and ET conceptualised and designed the study. CCO collected the data. CCO, SPM and AM analysed and interpreted the data. CCO drafted the initial manuscript. All authors revised the manuscript for important intellectual content. ET obtained funding for this study and is responsible for the overall content. All authors approved the final manuscript.

  • Funding This research is supported by the National Institute on Drug Abuse of the National Institutes of Health and FDA Center for Tobacco Products (CTP) under award number R01DA048529.

  • Disclaimer The content of this research is solely the responsibility of the authors and does not necessarily reflect the views of the National Institutes of Health or FDA.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.